Sign In
Buy EW
$86.00
-1.66 (-1.89%)
At Close: Jun 03, 2026
Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?
08:50am, Wednesday, 14'th Jan 2026
EW benefits from strong TAVR and TMTT momentum, but macro pressures and FX headwinds cloud the near-term outlook.
Edwards Lifesciences Corporation (EW) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
04:55pm, Monday, 12'th Jan 2026
Edwards Lifesciences Corporation (EW) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Edwards Comments on JenaValve Acquisition
06:48pm, Friday, 09'th Jan 2026
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission
FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve
04:17pm, Friday, 09'th Jan 2026
The U.S. Federal Trade Commission won a ruling on Friday blocking Edwards Lifesciences Corp's acquisition of Jenavalve Technology Inc, court records showed.
Econ Financial Services Corp Acquires 15,836 Shares of Edwards Lifesciences Corporation $EW
04:52am, Friday, 02'nd Jan 2026
Econ Financial Services Corp lifted its holdings in Edwards Lifesciences Corporation (NYSE: EW) by 139.4% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned
EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy
01:21pm, Friday, 26'th Dec 2025
Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.
HALPER SADEH LLC ENCOURAGES EDWARDS LIFESCIENCES CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
12:45pm, Wednesday, 24'th Dec 2025
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investi
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
09:00am, Tuesday, 23'rd Dec 2025
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal appr
4 Large-Cap MedTech Stocks to Keep Winning Streaks Alive in 2026
12:11pm, Monday, 22'nd Dec 2025
Four large-cap MedTech leaders, MDT, ISRG, CAH, EW, appear well-positioned to extend their winning streaks in 2026 on resilient procedure demand and innovation.
Edwards Lifesciences Corporation $EW Stake Increased by Thrivent Financial for Lutherans
05:04am, Sunday, 21'st Dec 2025
Thrivent Financial for Lutherans lifted its holdings in Edwards Lifesciences Corporation (NYSE: EW) by 24.6% in the undefined quarter, according to the company in its most recent disclosure with the S
Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:05am, Thursday, 18'th Dec 2025
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026. Bernard Zovighian, c
Should You Continue to Hold EW Stock in Your Portfolio?
09:11am, Thursday, 11'th Dec 2025
Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.
Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript
08:52am, Thursday, 11'th Dec 2025
Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript
Arrowstreet Capital Limited Partnership Sells 112,182 Shares of Edwards Lifesciences Corporation $EW
03:27am, Wednesday, 10'th Dec 2025
Arrowstreet Capital Limited Partnership reduced its position in Edwards Lifesciences Corporation (NYSE: EW) by 42.2% in the second quarter, according to the company in its most recent Form 13F filing
Edwards Lifesciences Corporation $EW Shares Sold by Edgestream Partners L.P.
04:50am, Monday, 08'th Dec 2025
Edgestream Partners L.P. lowered its stake in Edwards Lifesciences Corporation (NYSE: EW) by 97.0% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institut
